Lipohypertrophy and the artificial pancreas: Is this an issue?

Journal of Diabetes Science and Technology

Volumn 8, Issue 5, 2014, Pages 915-917

  Heinemann, Lutz ^a   Hirsch, Larry ^b   Hovorka, Roman ^c  

^a Science and Co   (Germany)

^b BD Technologies   (United States)

^c NONE   (United Kingdom)

Author keywords

Artificial pancreas; Injection sites; Insulin action; Lipohypertrophy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

INSULIN;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DRUG ABSORPTION; GLUCOSE SENSOR; HUMAN; INSULIN INFUSION; INSULIN TREATMENT; LETTER; LIPOHYPERTROPHY; LOCAL SKIN REACTION; SKINFOLD THICKNESS; SUBCUTANEOUS FAT; TISSUE INJURY; ADVERSE EFFECTS; HYPERTROPHY; PATHOLOGY;

HUMANS; HYPERTROPHY; PANCREAS, ARTIFICIAL; SUBCUTANEOUS FAT;

EID: 84930709007     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814538941     Document Type: Letter

References (13)

1. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445-453.
2. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-Treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104:106-110.
3. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152:622-628.
4. Kolendorf K, Bojsen J, Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm Metab Res. 1983;15:274-278.
5. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med. 1990;7: 795-799.
6. Johannsson UB, Wredling RAM, Lins PE, Adamson U. Reproducability of insulin absorption with insulin lispro and regular insulin during CSII. Diabetes. 1998;47 (suppl 1):A10.
7. Heinemann L. Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy? J Diabetes Sci Technol. 2010;4:750-753.
8. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231-236.
9. Omar MA, El-Kafoury AA, El-Araby RI. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Res Notes. 2011;4:290.
10. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23:1-12.
11. Lindpointner S, Korsatko S, Kohler G, et al. Use of the site of subcutaneous insulin administration for the measurement of glucose in patients with type 1 diabetes. Diabetes Care. 2010;33:595-601.
12. Gibney MA, Arce CH, Byron KJ, Hirsch L. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26: 1519-1530.
13. Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites-measurement of the distance from skin to muscle and rationale for use of shorter-length needles for subcutaneous insulin therapy. In review.